This announcement is a separate document:
騰盛博藥-B：內幕消息國家藥品監督管理局批准中國首個用於治療新冠肺炎的創新中和抗體聯合療法
BRII-B: INSIDE INFORMATION THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION APPROVES NOVEL NEUTRALIZING ANTIBODY COMBINATION THERAPY FOR THE TREATMENT OF COVID-19 IN CHINA
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.